Molecular Biomarkers in Delirium and Dementia

What this Trial Is About

Researchers are investigating biomarkers in cerebrospinal fluid (CSF) and blood samples from patients experiencing delirium, a serious condition marked by sudden changes in attention, awareness, and thinking. The study aims to better understand how delirium relates to dementia, as both conditions share clinical features and may have linked biological causes. This research could reveal early molecular changes important for dementia development. Participants are patients with acute hip fractures who may undergo hip fracture surgery, which is observed in this study. The project collects CSF and serum samples to analyze biomarkers related to delirium and dementia. No experimental treatments are given, as this is an observational study focused on understanding disease mechanisms. During the hospital stay, delirium is monitored daily until five days post-surgery or discharge. Cognitive changes related to dementia are evaluated for up to 48 months after participation begins. The study involves collecting clinical data, samples, and cognitive assessments over time to explore how delirium may influence dementia progression. Participants' health and safety are observed throughout the follow-up period, which extends until the end date in 2027.

Analyses of Cerebrospinalfluid in Patients With Delirium